Lethal double infection with Acremonium strictum and Aspergillus fumigatus during induction chemotherapy in a child with ALL

Pediatric Blood and Cancer

Volumn 49, Issue 6, 2007, Pages 858-861

  Foell, J L ^a   Fischer, M ^a   Seibold, M ^b   Borneff Lipp, M ^a   Wawer, A ^d   Horneff, G ^a,c   Burdach, S ^a,d  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

^c Asklepios Klinik   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acremonium; Acute lymphoblastic leukemia; Aspergillus; Hematological malignancies; Invasive fungal infection; Neutropenia

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; VORICONAZOLE;

ACREMONIUM; ACREMONIUM STRICTUM; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BRONCHOSCOPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FUNGUS CULTURE; FUSARIUM; HISTOPATHOLOGY; HUMAN; MALE; MORBIDITY; MORTALITY; MYCOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY DISTRESS;

ACREMONIUM; ADOLESCENT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; FATAL OUTCOME; HUMANS; LEUKEMIA, B-CELL, ACUTE; MALE; NEUTROPENIA; PEPTIDES, CYCLIC;

EID: 34948862136     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20756     Document Type: Article

References (23)

1. Walsh TJ, Hiemenz JW, Anaissie EJ. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin North Am 1996;10:365-400.
2. van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) 1998;77:246-254.
3. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management. Blood 1997;90:999-1008.
4. Walsh TJ, Groll AH. Emerging fungal pathogens: Evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis 1999;1:247-261.
5. Girmenia C, Pagano L, Corvatta L, et al. The epidemiology of fusariosis in patients with haematological diseases. Gimema infection programme. Br J Haematol 2000;111:272-276.
6. Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and fusarium infection. Cancer 2003;98:315-319.
7. Musa MO, Al Eisa A, Halim M, et al. The spectrum of fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: A single institution experience over 10 years. Br J Haematol 2000;108:544-548.
8. Dignani MC, Anaissie EJ. Human fusariosis. Clin Microbiol Infect 2004;10:67-75.
9. Mangini C, de Camargo B. Fungal infection due to fusarium (spp) in children with refractory hematologic malignancies. Med Pediatr Oncol 1999;32:149-150.
10. Ariffin H, Ariffin W, Mohamed M, et al. Management of systemic fusarium infection in children with leukemia. Med Pediatr Oncol 1999;33:598-599.
11. Liu K, Howell DN, Perfect JR, et al. Morphologic criteria for the preliminary identification of fusarium, paecilomyces, and acremonium species by histopathology. Am J Clin Pathol 1998;109:45-54.
12. Chang YH, Huang LM, Hsueh PR, et al. Acremonium pyomyositis in a pediatric patient with acute leukemia. Pediatr Blood Cancer 2005;44:521-524.
13. Guarro J, Gams W, Pujol I, et al. Acremonium species: New emerging fungal opportunists - In vitro antifungal susceptibilities and review. Clin Infect Dis 1997;25:1222-1229.
14. Yalaz M, Hilmioglu S, Metin D, et al. Fatal disseminated acremonium strictum infection in a preterm newborn: A very rare cause of neonatal septicaemia. J Med Microbiol 2003;52:835-837.
15. Mattei D, Mordini N, Lo Nigro C, et al. Successful treatment of acremonium fungemia with voriconazole. Mycoses 2003;46:511-514.
16. Novicki TJ, LaFe K, Bui L, et al. Genetic diversity among clinical isolates of acremonium strictum determined during an investigation of a fatal mycosis. J Clin Microbiol 2003;41:2623-2628.
17. Espinel-Ingroff A, Bartlett M, Chaturvedi V, et al. Optimal susceptibility testing conditions for detection of azole resistance in aspergillus spp.: Nccls collaborative evaluation. National committee for clinical laboratory standards. Antimicrob Agents Chemother 2001;45:1828-1835.
18. Anaissie EJ, Kuchar RT, Rex JH, et al. Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: A new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001;33:1871-1878.
19. Walsh TJ. Primary cutaneous aspergillosis - An emerging infection among immunocompromised patients. Clin Infect Dis 1998;27:453-457.
20. Herbrecht R. Posaconazole: A potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract 2004;58:612-624.
21. Rothe A, Seibold M, Hoppe T, et al. Combination therapy of disseminated fusarium oxysporum infection with terbinafine and amphotericin b. Ann Hematol 2004;83:394-397.
22. Roilides E, Bibashi E, Acritidou E, et al. Acremonium fungemia in two immunocompromised children. Pediatr Infect Dis J 1995;14:548-550.
23. Lau YL, Yuen KY, Lee CW, et al. Invasive acremonium falciforme infection in a patient with severe combined immunodeficiency. Clin Infect Dis 1995;20:197-198.